Enhancing incretin action for the treatment of type 2 diabetes.
about
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteersCommon medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Interactions between kidney disease and diabetes: dangerous liaisonsEmerging utility of once-weekly exenatide in patients with type 2 diabetesDPP4 in DiabetesA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondElevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brainInsulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndromePharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjectsInhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberineSaxagliptin overview: special focus on safety and adverse effectsEffect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in ratsAntidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeksCombination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation.Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular riskThe dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivoEffect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus.Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataThe G protein-coupled receptor P2Y14 influences insulin release and smooth muscle function in mice.Weight considerations in pharmacotherapy for type 2 diabetesCardiovascular effects of incretin therapy in diabetes care.Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitusExenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.Safety and adverse effects associated with GLP-1 analogues.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alonePharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes.Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes.Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trialDipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis.RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice.Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.Managing Type 2 Diabetes Mellitus through Periodical Hospital Visits in the Aftermath of the Great East Japan Earthquake Disaster: A Retrospective Case Series.
P2860
Q24658008-627B4260-6933-48B3-98B1-21830FF1699DQ26740253-7F660F42-6E46-47E8-BEF9-E53AA395F0D0Q26740630-0227ADC0-C537-4486-8577-A05544814616Q26777320-7131253E-34AD-428C-9A07-2B18903D5E6DQ26797335-7AC0DC0F-D042-461A-B0E3-7310B2E133F5Q26799389-169EAF1D-00E2-46FA-B4C5-A2BE36672AE7Q27003253-844F4F8C-670F-47CF-8F7E-655B2FAAE537Q27008997-7751B0E2-8EA1-4642-A833-D0C063D046F0Q28252893-2BF8519C-D604-4409-BE6B-BBE391977FD7Q28253310-AC7725AA-AFD8-4DFA-89F4-EDABFCCB0C36Q28278863-4D7AD7C0-3AF5-4E4E-AE9A-936C4AA22897Q28730724-8B175105-C0C5-4D2E-8FAE-6F1FF7E158A8Q33224640-ACA325E1-8C10-4039-ABE5-8DE55E11CC0AQ33585633-9EE8D8BB-E6AD-4B73-BB33-E40390D47EA3Q33609727-0816ED82-D542-409F-BADC-47E54D2385DAQ33755744-0B42283B-14D4-427D-9BBB-9F0CB0A08C7CQ33785308-B459D4DA-164D-4BD1-87B1-3C297C8C11ADQ33789529-C5FD3663-2726-4E76-986C-9C1EE432D21FQ33813768-B6DFC321-ABBE-4638-8E48-0D8531644871Q33849176-9917828D-4619-4FFE-8943-16A157A4DDA0Q34016283-3B581C05-7CE3-4B4D-B98C-615354C883CAQ34064982-7F65B51F-6087-45FE-BAF2-0BCB5654B85DQ34128612-58D7FB0A-8ED2-4237-8B39-B05900C44945Q34141128-E8DDC010-F261-4A51-BD58-B0131A6D1D7DQ34159414-561B3E3A-7351-4CA6-8253-91344BFF5368Q34171759-D8915316-626E-4BA5-968C-737750C3C212Q34496741-DC9BC248-89F8-4AF4-8E10-3D43D12C5899Q34530205-8A185C3B-9B39-43C4-BCBF-EA4356600CB7Q34581781-887844A6-8C97-4BD9-974E-2C1146F8BAC6Q34608300-7B188986-23BC-4E9F-AF69-4B3F3D94957CQ34620493-7CF3ADB5-9907-4F34-B3CE-D1A08155C927Q34620565-6F80FE4E-A8BA-4F5C-9EFA-119289133E9AQ34745045-0B766E1F-3E34-417C-AB10-0C674143F69DQ35026483-85F4DCD0-02EF-48E3-99F3-DBCA3C4B7394Q35067242-E1E962FB-A340-4B34-B48D-7030DC83CA61Q35120585-DBABD7F0-464A-4827-8D9E-64167CC42CDCQ35159576-0FECE0D6-EA90-4289-A586-67B2822E1E7BQ35175990-DA1D356C-1981-47BA-8200-AA4CDDF1BA70Q35250506-D684A4F3-1A6F-4AC1-9212-8DA92FE4134CQ35577388-98C14D71-2EED-40B5-95CA-60F564860266
P2860
Enhancing incretin action for the treatment of type 2 diabetes.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Enhancing incretin action for the treatment of type 2 diabetes.
@ast
Enhancing incretin action for the treatment of type 2 diabetes.
@en
type
label
Enhancing incretin action for the treatment of type 2 diabetes.
@ast
Enhancing incretin action for the treatment of type 2 diabetes.
@en
prefLabel
Enhancing incretin action for the treatment of type 2 diabetes.
@ast
Enhancing incretin action for the treatment of type 2 diabetes.
@en
P1433
P1476
Enhancing incretin action for the treatment of type 2 diabetes.
@en
P304
P356
10.2337/DIACARE.26.10.2929
P407
P577
2003-10-01T00:00:00Z